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ABSTRACT 
The hypoglossal nucleus was recently identified as a key brain region in which the presence of 
TDP-43 pathology could accurately discriminate TDP-43 proteinopathy cases with clinical 
amyotrophic lateral sclerosis (ALS). The objective of the present study was to assess the 
hypoglossal nucleus in behavioral variant frontotemporal dementia (bvFTD), and determine 
whether TDP-43 in this region is associated with clinical ALS. Twenty-nine cases with 
neuropathological FTLD-TDP and clinical bvFTD that had not been previously assessed for 
hypoglossal TDP-43 pathology were included in this study. Of these 29 cases, 41% (n=12) had a 
dual diagnosis of bvFTD-ALS at presentation, all 100% (n=12) of which demonstrated hypoglossal 
TDP-43 pathology. Of the 59% (n=17) cohort that presented with pure bvFTD, 35% (n=6) were 
identified with hypoglossal TDP-43 pathology. Review of the case files of all pure bvFTD cases 
revealed evidence of possible or probable ALS in 5 of the 6 hypoglossal-positive cases (83%) 
towards the end of disease, and this was absent from all cases without such pathology. In 
conclusion, the present study validates grading the presence of TDP-43 in the hypoglossal nucleus 
for the pathological identification of bvFTD cases with clinical ALS, and extends this to include the 
identification of cases with possible ALS at end-stage.  
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1. INTRODUCTION 
The TAR DNA-binding protein 43 (TDP-43) in behavioral variant frontotemporal dementia (bvFTD) 
was recently proposed to have a regional distribution, initiated in the orbitofrontal cortex and 
amygdala before progressing to the frontal and temporal cortices, eventually involving the motor 
system, visual cortex and cerebellum [5]. Although the majority of bvFTD cases were found to 
have TDP-43 pathology in motor system regions, less than half of these demonstrated clinical 
features suggestive or diagnostic of amyotrophic lateral sclerosis (ALS) [5].  
 
In our recent analysis, the hypoglossal nucleus emerged as a key brain region in which the 
presence of TDP-43 pathology could accurately discriminate ‘TDP-43opathy’ cases with coexistent 
clinical features of ALS [20]. However, TDP-43 pathology was seen in the hypoglossal nucleus of 
13% of the bvFTD cohort assessed [20]. Based on the premise that pathological deposition 
precedes clinical symptomology [4], the present study set out to determine if bvFTD cases with 
TDP-43 pathology in the hypoglossal nucleus had developed or were developing ALS by end-
stage. 
 
2. MATERIAL AND METHODS 
2.1 Case selection. Cases with bvFTD were selected from a neuropathological series of cases 
collected by the Sydney Brain Bank through regional brain donor programs. The brain donor 
programs hold approval from the Human Research Ethics Committees of The University of New 
South Wales, and comply with the statement on human experimentation issued by the National 
Health and Medical Research Council of Australia. All cases had previously undergone 
standardized detailed neuropathological characterization [8, 14]. Patients with bvFTD were 
diagnosed during life by experienced clinicians using standard clinical diagnostic criteria [13, 16] 
following a medical interview, cognitive testing and an informant history. Standardized tests were 
used to longitudinally follow patients and controls, with their last assessments performed within 14 
months of death. Clinical data were ascertained from an integrated clinical and neuropathological 
database and by retrospective review of patient clinical files. This research project was approved 
by the Human Research Ethics Committee of the University of New South Wales. Cases with 
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neuropathological FTLD-TDP and clinical bvFTD not previously analysed in [20] were included in 
this study (n=27) as well as two bvFTD cases previously assessed that met clinical criteria for 
possible ALS by endstage (n=2/22 from [20] Figure 2c). Of these 29 bvFTD cases, 59% (n=17) did 
not have a clinical diagnosis of possible or probable ALS at onset and are referred to here as ‘pure 
bvFTD’ while the others had both bvFTD and possible or probable ALS at onset (n=12, 41%).  
 
2.2 Analysis of TDP-43 pathology in the hypoglossal nucleus. Formalin-fixed, paraffin-
embedded tissue blocks of the hypoglossal nucleus were sectioned at 10 μm and immunostained 
with the anti-phospho TDP-43 monoclonal antibody (1:80 000, TIP-PTD-M01, Cosmo Bio). All 
slides were counterstained with haematoxylin to visualize neurons and other cells. In cases 
identified to have TDP-43 cytoplasmic inclusions in the hypoglossal nucleus (Figure 1), TDP-43 
immunostaining was also performed on sections from the motor cortex and where available, the 
spinal cord. The severity of TDP-43 pathology in each section was graded on a four-point severity 
scale: 0 = no detectable pathology, 1 = mild pathology, 2 = moderate and 3 = frequent pathology. 
Assessments of TDP-43 pathology were performed by two raters blind to case details with an inter- 
and intra-rater variance of <5%. 
 
2.3 Severity of upper and lower motor neuron loss. The severity of Betz cell loss in the motor 
cortex and motor neuron loss in the anterior horn of the spinal cord was graded semi-quantitatively 
using haematoxylin and eosin stained sections, an Olympus microscope at 100-200x magnification 
and a 5-point severity scale: 0 = no loss, 1 = mild loss, 2 = moderate loss, 3 = severe loss, 4 = 
complete loss. Assessments of cell loss were performed by two raters blind to case details with an 
inter- and intra-rater variance of <5%.  
XX Insert Figure 1 here XX 
2.4 Genetic analyses.  
2.4.1. Frozen tissue. Frozen tissue was available in 75% (n=9) of bvFTD-ALS and 76% (n=12) of 
pure bvFTD cases, and was screened for genetic mutations (C9ORF72 and GRN) using previously 
published methods [12, 17].  
XX Insert Table 1 here XX 
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2.4.2. P62 and dipeptide repeat proteins in cerebellum. Formalin-fixed, paraffin-embedded 
tissue blocks of the cerebellum cortex were available for 67% (n=8) of bvFTD-ALS and 76% (n=13) 
pure bvFTD cases, and were sectioned at 10 μm, and immunostained with antibodies to p62 (cat 
#610833, BD Biosciences, 1:500), phosphorylated TDP-43 (TIP-PTD-M01, Cosmo Bio, 1:80 000) 
and poly-GA (specificity detailed previously [15], courtesy of Prof M Hasegawa, 1:1500). All slides 
were counterstained with haematoxylin to visualize neurons, and assessments for P62 and 
dipeptide repeat protein inclusions characteristic of C9ORF72 expansions [2, 15] were performed 
at 200-400x magnification.  
 
2.5 Statistical analyses. Statistical analyses were performed using SPSS (IBM SPSS statistics 
version 21; SPSS Inc.), with p-values < 0.05 taken as significant. Demographic data were plotted 
and checked for normality of distribution by Kolmogorov-Smirnov tests. Parametric data (age at 
onset and death, disease duration, postmortem interval, brainstem weight, brain weight) were 
assessed across participant groups via one-way ANOVA followed by Bonferroni post hoc tests. 
Variables showing non-parametric distribution were analysed using chi-square analyses (gender, 
mutation).  
 
3. RESULTS  
3.1 TDP-43 pathology in bvFTD cases. TDP-43 cytoplasmic inclusions were identified in the 
hypoglossal nucleus of 100% (n=12) of the bvFTD-ALS cases and 29% (n=5) of the pure bvFTD 
cases. Punctate TDP-43 granules similar to that previously described [11] were identified in the 
hypoglossal nucleus and spinal cord in a further 6% (n=1) of the pure bvFTD cases (Figure 1). All 
bvFTD cases with TDP-43 pathology in the hypoglossal nucleus (n=6) were found to have TDP-43 
pathology in the motor cortex (Table 2) and a further 55% (n=6) of bvFTD cases without TDP-43 
pathology in the hypoglossal nucleus demonstrated TDP-43 pathology in the motor cortex.  
 
XX Insert Table 2 here XX 
3.2 End-stage ALS in bvFTD cohort. The clinical records of all pure bvFTD cases (n=17) were 
retrospectively reviewed by a clinical neurologist (MK). Based on the Awaji-shima consensus 
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recommendations for ALS [10], motor impairment consistent with ‘possible’ and ‘probable’ ALS 
was identified in 24% (n=4) and 6% (n=1) cases respectively, in the final clinical reports performed 
outside of specialist ALS clinics.   
 
3.3 Evidence of genetic abnormalities in the bvFTD cohort.  
3.3.1. Gene screening. Frozen tissue was available in 9/12 bvFTD-ALS cases. A C9ORF72 
expansion was identified in 33% (n=3/9) of the bvFTD-ALS cases and 62% (n=8) of the pure 
bvFTD cases (Table 1). A GRN mutation was identified in 24% (n=4) of the pure bvFTD cases 
only.  
 
3.3.2. P62 and dipeptide repeat proteins in cerebellum. All bvFTD-ALS (n=5) and pure bvFTD 
cases (n=9) assessed for both C9ORF72 expansions in frozen tissue and C9ORF72-distinct 
histopathology in cerebellar sections demonstrated consistent results with both methods. Of the 
bvFTD-ALS cases without available frozen tissue (3/12), C9ORF72-specific cerebellar pathology 
was identified in 33% bvFTD-ALS (1/3). C9ORF72-specific cerebellar pathology was not seen in 
67% bvFTD-ALS (n=2) and 100% pure bvFTD cases (n=4).  
 
3.4 Family history 
3.4.1. Familial bvFTD. Familial disease was present in 33% (n=4) of bvFTD-ALS and 76% (n=13) 
of pure bvFTD cases. For bvFTD-ALS, a C9ORF72 expansion was identified in 75% (n=3/4). 
Within the familial bvFTD cohort, 62% (n=8/13) demonstrated a C9ORF72 expansion, 31% 
(n=4/13) demonstrated a GRN mutation, and no mutation was identified in 8% (n=1/13).  
 
3.4.2. Family history of ALS. A family history for ALS was identified in 8% (n=1/12) of bvFTD-ALS 
cases and 24% (n=4/17) of pure bvFTD cases. All cases with a positive family history for ALS 
harbored a C9ORF72 expansion (n=5), and 80% (n=4) demonstrated maternal inheritance.  
 
3.5 Clinicopathological findings. Of the pure bvFTD cases identified to have TDP-43 pathology 
in the hypoglossal nucleus (n=6), 83% (n=5) corresponded with a retrospective diagnosis of end-
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stage possible or probable ALS. The remaining case (n=1) demonstrated no end-stage signs of 
motor dysfunction although the patient’s very slim stature in the final years of disease was of note, 
particularly since she had been significantly overweight for the majority of the disease course. 
There was no indication of clinical ALS in 100% (n=11) of the pure bvFTD cases without TDP-43 
pathology in the hypoglossal nucleus. 
 
3.6 Demographic features. As can be seen in Table 1, age at disease onset and death, gender 
and postmortem interval did not differ significantly across bvFTD groups (all p-values > 0.1). 
Disease duration was significantly shorter in bvFTD-ALS cases compared to pure bvFTD cases as 
a whole (p < 0.005), but this difference was driven by pure bvFTD cases without TDP-43 pathology 
in the hypoglossal nucleus (p < 0.005). The frequency of C9ORF72 expansions was not significant 
between bvFTD-ALS and pure bvFTD cases as a whole. However, the separation of pure bvFTD 
cases by TDP-43 pathology in the hypoglossal nucleus revealed a higher frequency of C9ORF72 
expansions in pure bvFTD cases with TDP-43 pathology in the hypoglossal nucleus compared to 
without (p < 0.05), and this significance held even in comparison to bvFTD-ALS cases (p < 0.05). 
GRN expansions were only identified in pure bvFTD cases without TDP-43 pathology in the 
hypoglossal nucleus (p < 0.05 compared to other groups). Family history for ALS was more 
prevalent in pure bvFTD cases with TDP-43 in the hypoglossal nucleus, but this did not reach 
significance compared to other bvFTD cohorts (p = 0.06).   
 
3.7 Brain and brainstem weights. A comparison of formalin-fixed brain and brainstem weights 
revealed that pure bvFTD cases without TDP-43 pathology in the hypoglossal nucleus (bvFTDhyp-ve 
) had a significantly lower weight compared to bvFTD-ALS cases (mean ± standard deviation brain 
weight: 871.0 ± 146.0 in bvFTDhyp-ve; 1160.8 ± 146.4 in bvFTD-ALS, p < 0.005 between groups; 
mean ± standard deviation brainstem weight: 23.7 ± 2.9 in bvFTDhyp-ve; 28.0 ± 3.8 in bvFTD-ALS, p 
< 0.05 between groups), with bvFTD cases with TDP-43 pathology in the hypoglossal nucleus 
(bvFTDhyp+ve ) and end-stage ALS demonstrating an intermediate brain and brainstem weight that 
was not significantly different from either bvFTD-ALS or bvFTDhyp-ve cases (mean ± standard 
deviation: 1074.1 ± 181.5 brain weight, 26.0 ± 2.8 brainstem weight, p>0.05 compared to bvFTD-
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ALS and bvFTDhyp-ve cases) (Figure 2). There was no interaction between age or mutation carrier 
with brain and brainstem weights across groups.  
XX Insert Figure 2 here XX 
 
4. DISCUSSION 
The present study has assessed the hypoglossal nucleus of bvFTD cases for the presence of 
TDP-43 pathology as an indicator of clinical ALS, and expands on our recent probabilistic 
statement [20] by establishing that hypoglossal TDP-43 immunoreactivity identifies bvFTD cases 
with possible ALS. Specifically, TDP-43 cytoplasmic inclusions were identified in the hypoglossal 
nucleus of 100% bvFTD-ALS cases, and 35% of pure bvFTD cases. A review of the final clinical 
assessments performed outside of ALS specialist clinics revealed possible or probable ALS [10] in 
5 of the 6 (83%) pure bvFTD cases with TDP-43 pathology in the hypoglossal nucleus, but not in 
any case without TDP-43 pathology in the hypoglossal nucleus. These findings validate grading 
the presence of TDP-43 cytoplasmic inclusions in the hypoglossal nucleus for the pathological 
identification of bvFTD cases with clinical ALS, and extend this to include the identification of cases 
with possible ALS.  
 
End-stage clinical and postmortem histopathological assessments are commonly assigned lesser 
importance because they represent cross-sectional assessments at the end of a disease course. 
However, given that pathological changes often precede clinical symptomology [4], the 
identification of early ALS in FTD cohorts provides a unique platform in which to investigate cases 
at the interval between the accumulation of underlying histopathological changes and the full 
manifestation of clinical features. The identification of features characteristic of patients 
representative of this intermission has important implications for research into preclinical markers 
of disease. In the present series, 94% of bvFTD cases identified to have TDP-43 pathology in the 
hypoglossal nucleus demonstrated clinical ALS at some point over the course of their disease. 
However, 5% showed no signs of motor dysfunction by end-stage despite the deposition of TDP-
43 pathology across the spinal cord, hypoglossal nucleus and motor cortex. Importantly, all of the 
bvFTD cases identified to have TDP-43 pathology in the hypoglossal nucleus and clinical ALS 
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demonstrated well-formed TDP-43 inclusions whereas the one patient without signs of motor 
dysfunction by end stage showed only punctate TDP-43 granules. We postulate that this patient 
developed either rapid end-stage ALS that had not been detected, or came to autopsy prior to this 
clinical manifestation. However, this could not be ascertained due to the lack of clinical 
assessments in the final 5 months of this patient’s life. Notably however, the patient became very 
slim in the final years of life and this was distinct given that the patient had been obese for the 
majority of the disease duration. Although an isolated case, a significant loss in body mass index 
(BMI) in patients with bvFTD may precede ALS, highlighting the importance of including BMI in 
longitudinal assessments of patients with bvFTD to end-stage [1].  
 
The recent topographical staging of TDP-43 pathology in bvFTD and ALS [6, 7] demonstrated that 
TDP-43 initiated in the motor system network in ALS is also seen in the majority of bvFTD cases, 
despite the absence of ALS in over 50% of these [6, 21]. In a recent analysis [21], we identified the 
hypoglossal nucleus as a key brain region in discriminating between cases with and without ALS 
and the present study corroborates this finding in bvFTD cases. Further support for the 
segregation of bvFTD cases by TDP-43 inclusions in the hypoglossal nucleus was evidenced here 
by differences in disease duration and postmortem brain weights, with ‘intermediate’ levels of 
atrophy in bvFTD cases with end-stage ALS (Figure 2). Motor system degeneration is 
characteristic of ALS [8] but neuroimaging studies have reported mild and often times variable 
atrophy in these regions rather than substantial atrophy [3, 9]. In contrast, the brainstem is one of 
the earliest regions affected in bvFTD due to its considerable non-motor cortical connectivity with 
cortical regions affected early in the disease [19], Although sampled at the end of disease, the 
greater brain and brainstem weights seen in bvFTD cases with TDP-43 pathology in the 
hypoglossal nucleus suggest that structural analyses of brainstem integrity earlier in the disease 
course may be able to delineate these cases. Unfortunately, neuroimaging scans were not 
available in this present cohort and the feasibility of this could not be assessed here.  
 
No GRN mutations were identified in bvFTD cases with TDP-43 pathology in the hypoglossal 
nucleus, and this converges with the very low prevalence of GRN mutations in ALS [18] to suggest 
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that GRN mutations may identify bvFTD patients that have a lower risk of TDP-43 pathology in the 
hypoglossal nucleus and clinical ALS. Importantly, 50% of bvFTD cases with TDP-43 pathology in 
the hypoglossal nucleus harbored a C9ORF72 expansion and this was particularly prevalent in 
cases that had not been diagnosed with ALS at presentation (83%), emphasizing the need to 
follow C9ORF72-bvFTD cases longitudinally for early clinical signs of ALS.  
  
In terms of limitations it is accepted that there remains a period of time between the final clinical 
assessment and patient death, during which further clinical features may have developed. 
Although such a time lapse is difficult to circumvent, the replication of our current results in larger 
cohorts of patients represents an important avenue for future research to ascertain whether TDP-
43 pathology in the hypoglossal nucleus precedes clinical ALS symptomology.  
 
In summary, the present study validates the application of our recently proposed probabilistic 
statement for the pathological identification of TDP-43 proteinopathy cases with a clinical ALS 
diagnosis, extending this to include cases with possible ALS by end stage. At present, hypoglossal 
nerve function is not routinely assessed in patients with bvFTD and we suggest the inclusion of 
simple measures of hypoglossal function and BMI in longitudinal studies of patients with bvFTD, 
particularly that harbor a C9ORF72 mutation, in order to identify potential markers of early ALS in 
these cohorts. Specifically, screening patients with techniques that assess disease involvement, 
including electromyographic examination of bulbar muscles, may increase the recognition of 
patients with bvFTD who will develop concurrent ALS. Future clinicopathological assessments in 
large cohorts of patients with bvFTD that have been well followed longitudinally to end-stage are 
needed to determine if TDP-43 pathology in the hypoglossal nucleus precedes clinical ALS 
symptomology and associated markers of early ALS.  
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 bvFTD-ALS bvFTD bvFTDhyp-ve bvFTDhyp+ve 
N (% male) 12 (58%) 17 (59%) 11 (64%) 6 (50%) 
Age at onset 64 ± 8 61 ± 7 62 ± 8 59 ± 6 
Age at death 66 ± 8 67 ± 7 69 ± 8 65 ± 6 
Disease duration 2 ± 1 a 6 ± 4 d 7 ± 4 5 ± 4 
Postmortem interval 29.5 ± 15.7 21.4 ± 17.0 16.8 ± 13.8 29.7 ± 20.5 
C9ORF72 carrier  33% b 47%  27% b 83% 
GRN carrier (% screened) 0% c 24% 36% 0% c 
Familial bvFTD (% cohort) 33% 76% e 73% f 83% f 
Family history of ALS 8% 24% 9% 50% 
TDP subtype (A/B/C/D) 6/6/0/0 10/5/2/0 6/3/2/0 4/2/0/0 
Table 1. Demographic features across bvFTD-ALS, bvFTD cases as a whole, and separated into cases with TDP-43 in the hypoglossal 
nucleus (bvFTDhyp+ve ) and without bvFTDhyp-ve). a p<0.005 compared to bvFTDhyp-ve, b p<0.05 compared to bvFTDhyp+ve, c p<0.05 compared to 
bvFTDhyp-ve. d p<0.005 compared to bvFTD-ALS, e p<0.05 compared to bvFTD-ALS, f p=0.06 compared to bvFTD-ALS 
 
 
 14 
 
# M
/F 
AD 
(y) 
AO
(y) 
DD 
(y) 
TDP 
in 
HYP 
Hyp 
cell 
loss 
MC 
hem 
TDP 
in 
MC  
Betz 
cell 
TDP 
Betz 
cell 
loss 
TDP 
in 
SC 
SC 
cell 
loss 
TDP 
type 
C9 
(frozen 
tissue) 
C9 
CB 
path 
ALS 
hist 
Final clinical 
records within 12 
months of death 
unless otherwise 
specified 
Retro dx 
1 F 65 62 3 +++ 
 
 
+++ R ++ + ++ n/a n/a A Yes Yes Yes, 
mat 
Pseudobulbar 
palsy 
Possible 
ALS 
2* M 65 63 2 +  ++ L +++ + ++ n/a n/a A Yes Yes No Weakness and 
wasting of arms 
Possible 
ALS 
3 M 66 60 5 +  ++ L ++ ++ +  n/a n/a B Yes Yes No Dysphagia Possible 
ALS 
4 F 55 53 2 ++  +++ L ++ +++ 0 
 
n/a n/a B n/a 
 
No No Within 6 months 
of death: 
dysarthria, 
dysphagia, limb 
fasciculation and 
weakness, rapid 
disease 
progression, lost 
12 kg over 5 
months 
Probable 
ALS 
5* M 63 50 7 ++ 
 
+ L + 0 0 
 
n/a n/a A Yes Yes Yes, 
mat 
Weakness in left 
foot and left hip  
Possible 
ALS 
6 F 75 63 12 + 
 
+ R + + 0 
 
GCI:
+++, 
NCI: 
+ 
+ A Yes Yes Yes, 
mat 
No signs of motor 
dysfunction 
recorded, 
patient’s slim 
stature notable 
since she had 
been significantly 
overweight for the 
majority of the 
disease  
No 
clinical 
ALS 
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Table 2. Demographic, pathological, genetic and clinical features of bvFTD cases identified to have TDP-43 in the hypoglossal nucleus. AD: 
Age death, AO: Age onset, DD: disease duration, C9: C9ORF72, CB path: Cerebellar pathology, HYP: hypoglossal nucleus, MC: motor cortex, SC: 
spinal cord, hem: hemisphere, CB: cerebellum, Ubi/DPR +ve: ubiquitin/dipeptide repeat protein positive, TDP-ve: TDP-43 negative, GCI: granular 
cytoplasmic inclusions, NCI: neuronal cytoplasmic inclusion, ALS hist: family history of ALS, mat: maternal, retro dx: retrospective diagnosis, n/a: not 
available. Histopathological changes were rated on a 4-point scale: 0 absent, + mild, ++ moderate, +++ severe. *Cases previously assessed [20]. 
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Figure 1. TDP-43 in the hypoglossal nucleus and spinal cord of bvFTD cases. TDP-43 
cytoplasmic inclusions (A top inset, case #1, B, case#4), punctate TDP-43 granules (A bottom 
inset, C) and TDP-43 glial inclusions (A) were identified in the hypoglossal nucleus of bvFTD 
cases. In one case (C, case #6), only punctate TDP-43 granules were present in the hypoglossal 
nucleus, and numerous TDP-43 granules with one cytoplasmic inclusion were observed in the 
spinal cord (D, case #6).  
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Figure 2. Brain and brainstem weights across bvFTD cases with TDP-43 in the hypoglossal 
nucleus and clinical ALS at presentation, bvFTD cases without TDP-43 in the hypoglossal 
nucleus and no evidence of ALS, and bvFTD cases with TDP-43 in the hypoglossal nucleus 
and clinical ALS at end-stage. Group comparisons revealed a significant difference between 
bvFTD cases with TDP-43 in the hypoglossal nucleus and clinical ALS compared to bvFTD cases 
without TDP-43 in the hypoglossal nucleus nor clinical ALS. BvFTD cases with TDP-43 in the 
hypoglossal nucleus found to have ALS at end-stage demonstrated intermediate brain and 
brainstem weights not significantly different from the other two cohorts.  
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